Although fungal infections contribute substantially to human morbidity and mortality, the
impact of these diseases on human health is not widely appreciated. Moreover, despite the …

Invasive fungal infections (IFI) are an emerging problem worldwide with invasive candidiasis
and candidemia responsible for the majority of cases. This is predominantly driven by the …

Abstract (See the editorial commentary by Lange, on pages 801–802.) For individuals with
human immunodeficiency virus (HIV) infection to fully benefit from potent combination …

The incidence of invasive mycoses is increasing, especially among patients who are
immunocompromised or hospitalized with serious underlying diseases. Such infections may …

Although the incidence of Pneumocystis pneumonia (PCP) has decreased since the
introduction of combination antiretroviral therapy, it remains an important cause of disease in …

The substantial decline in the Pneumocystis jirovecii pneumonia (PCP) incidence in HIV-
infected patients after the introduction of antiretroviral therapy (ART) in resource-rich settings …

Recent investigations have yielded both profound insights into the mechanisms required by
pathogenic fungi for virulence within the human host, as well as novel potential targets for …

Ibrexafungerp (formerly SCY-078 or MK-3118) is a first-in-class triterpenoid antifungal or
“fungerp” that inhibits biosynthesis of β-(1, 3)-D-glucan in the fungal cell wall, a mechanism …

Introduction: Pneumocystis jirovecii (PJ) is an opportunistic fungal pathogen that can cause
severe pneumonia in immunocompromised hosts. Risk factors for Pneumocystis jirovecii …

From the first descriptions of HIV/AIDS, the lung has been the site most frequently affected by
the disease. Most patients develop a pulmonary complication during the history of HIV …